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Abstract
Objective: The PTPN22 rs2476601 polymorphism is associated with rheumatoid arthritis (RA); nonetheless, the association is
weaker or absent in some southern European populations. The aim of the study was to evaluate the association between
the PTPN22 rs2476601 polymorphism and RA in Italian subjects and to compare our results with those of other European
countries, carrying out a meta-analysis of European data.
Methods: A total of 396 RA cases and 477 controls, all of Italic ancestry, were genotyped for PTPN22 rs2476601
polymorphism. Patients were tested for autoantibodies positivity. The meta-analysis was performed on 23 selected studies.
Results: The PTPN22 T1858 allele was significantly more frequent in RA patients compared to controls (5.7% vs. 3.7%,
p=0.045). No clear relationship arose with the autoantibodies tested. The 1858T allele frequency in Italian RA patients was
lower than the one described in northern European populations and similar to the frequency found in Spain, Turkey, Greece,
Tunisia. A clear-cut North-South gradient arose from the analysis.
Conclusions: The PTPN22 T1858 allele is associated with RA in the Italian population. A North-South gradient of the allele
frequency seems to exist in Europe, with a lower prevalence of the mutation in the Mediterranean area.
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Introduction
Genetic factors are thought to be responsible for up to 50–60%
of the rheumatoid arthritis (RA) liability [1]. The minor allele (T)
at 1858C.T( rs2476601) single-nucleotide polymorphism (SNP) in
the protein tyrosine phosphatase non-receptor type 22 (PTPN22,
gene map locus 1p13) gene has been extensively associated with
susceptibility to various autoimmune diseases [2]. The rs2476601
determines a R620W substitution resulting in a gain-of-function
form of the enzyme Lyp (encoded by the PTPN22 gene), thus
leading to a stronger suppression of early T cell activation process
[3]. The B cell compartment seems altered by this SNP as well [4].
The association of the PTPN22 1858C.T SNP with RA is well
established among many populations all over the world, especially
in anti-CCP (cyclic citrullinated peptides) antibodies positive RA
patients [5]. However, a weaker or a complete lack of association
has been reported in some southern European populations [6–9].
A review of the literature suggests a lower frequency of the T1858
allele in RA patients of the Mediterranean area. According to
Orozco et al., there was no association of PTPN22 1858C.T SNP
with early RA in Spain [6]. In Turkey, Sahin et al. found no
association of the 1858C.T SNP with RA [7]. Moreover, a lack
of association has also been reported in a Tunisian and in a Greek
population [8,9].
Although the role of PTPN22 rs2476601 SNP in autoimmunity
and its association with RA are undoubted, as recently confirmed
by genome-wide association analyses [10], it is important to take
into account geographical and anthropological differences when
performing genetic epidemiology studies.
To date, no data are available regarding the possible association
between PTPN22 1858C.T polymorphism and rheumatoid
arthritis in patients of Italic ancestry. The aims of the study were:
1. To evaluate the PTPN22 rs2476601 SNP distribution in an
Italian cohort; 2. To define, by means of a systematic review and
meta-analysis, the association between the PTPN22 1858C.T
polymorphism distribution in Europe and rheumatoid arthritis.
Methods
Ethical statement
The ethical approval for the study was obtained from the
Catholic University of the Sacred Heart Ethical Committee. All
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24292Table 2. Characteristics of the selected studies (n=24) concerning the association between PTPN22 1858C.T SNP and RA in
Europe.
Study Ref. Year Country Quality RA C/T-T/T Controls C/T-T/T RA total Controls total
Seldin et al. 16 2005 Finland 10 372 406 1030 1400
Plenge et al. 17 2005 Sweden 11.5 432 203 1513 874
Hinks et al. 18 2005 UK 11 289 114 886 595
Steer et al. 19 2005 UK 10 84 62 302 374
Wesoly et al. 20 2005 Netherlands 10 93 155 416 891
Zhernakova et al. 21 2005 Netherlands 10 42 88 151 528
Orozco et al. 22 2005 Spain 11.5 163 146 826 1036
Johansson et al. 5 2006 Sweden 12 35 71 89 360
Harrison et al. 23 2006 UK 10 179 109 686 566
Pierer et al. 24 2006 Germany 11.5 148 67 390 349
Viken et al. 25 2007 Norway 10.5 264 119 861 557
Lie et al. 26 2007 Norway 12.5 75 119 221 555
Kokkonen et al. 27 2007 Sweden 12 166 209 504 970
Majorczyk et al. 28 2007 Poland 11 61 118 173 543
Wesoly et al. 29 2007 Netherlands 10.5 183 55 661 284
Eike et al. 30 2008 Norway 11 213 191 686 952
Farago et al. 31 2008 Hungary 11 158 24 399 107
Starck et al. 32 2009 Slovakia 12.5 158 63 514 302
Sahin et al. 7 2009 Turkey 10.5 11 9 167 177
Chabchoub et al. 8 2009 Tunisia 11 7 12 150 236
Sfar et al. 33 2009 Tunisia 11 33 2 133 100
Morgan et al. 34 2009 UK 10 1324 705 4789 3630
Majorczyk et al. 35 2010 Poland 11 259 118 371 543
Present study - 2011 Italy - 44 34 396 477
doi:10.1371/journal.pone.0024292.t002
Table 1. Analysis of the association of PTPN22 1858C.T SNP with RA patients and healthy subjects.
Genotype
Group C/C C/T T/T T Allele HWE (p)
1 OR (95%CIs)
2 Allelic p
3
Females RA patients (n=313)
(mean age: 55.7613.7)
276 (91.6%) 36 (11.5%) 1 (0.3%) 38 (6.1%) 1.00 1.56 (0.95–2.55) 0.074
Healthy controls (n=377)
(mean age: 55.5614.1)
348 (92.3%) 28 (7.4%) 1 (0.3%) 30 (4.0%) 0.45
Males RA patients (n=83)
(mean age: 59.7612.2)
76 (91.6%) 7 (8.4%) 0 (0.0%) 7 (4.2%) 1.00 1.72 (0.54–5.52) 0.359
Healthy controls (n=100)
(mean age: 59.4612.0)
95 (95.0%) 5 (5.0%) 0 (0.0%) 5 (2.5%) 1.00
All RA patients (n=396)
(mean age: 56.6613.4)
352 (88.9%) 43 (10.9%) 1 (0.2%) 45 (5.7%) 1.00 1.58 (1.01–2.49) 0.045
Healthy controls (n=477)
(mean age: 56.3614.0)
443 (92.9%) 33 (6.9%) 1 (0.2%) 35 (3.7%) 0.48
1HWE: Hardy-Weinberg equilibrium.
2Odds ratios expressed as carriers of T1858 allele vs. non-carriers considering healthy controls as control group.
3Fisher’s exact test of odds ratios.
doi:10.1371/journal.pone.0024292.t001
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PTPN22 gene polymorphism and autoantibodies testing.
Case-control study
Population and setting. Cases were recruited from the
Division of Rheumatology of the Catholic University of the Sacred
Heart of Rome. Patients fulfilled at least four of the American
College of Rheumatology criteria for RA [11]. When looking back
at the database with characteristics of each patient, all satisfied the
2010 ACR criteria as well [12]. The controls sample includes
healthy subjects matched for age, sex and geographical origin with
case subjects.
In order to calculate the sample size, the following parameters
were used: power 80%, level of confidence 95%, estimated
frequency of PTPN22 T1858 allele in controls of 8.9% and of
15.1% in RA patients (based on the mean value of the European
studies). Sample size was estimated to be: 462 cases and 462
controls. Patients were recruited consecutively between January
2008 and December 2010 from the Division of Rheumatology of
the Catholic University of the Sacred Heart of Rome.
All patients’ sera were tested for the presence of anti-CCP, IgM
RF (rheumatoid factor) and IgA RF autoantibodies (ELISA
method, Axis-Shield Diagnostics, Dundee, UK for anti-CCP and
Orgentec diagnostika, Mainz, Germany for IgM and IgA RFs).
Genotyping. Genomic DNA was isolated from whole blood
through FlexiGene DNA kit (Qiagen, Valencia, CA) according to
the manufacturer instructions.
The PTPN22 1858C.T SNP was determined by the restriction
fragment length polymorphism-polymerase chain reaction (PCR)
based method as previously described [13], in all the patients and
controls. Briefly, oligonucleotides 59-TCACCAGCTTCCTCAAC-
CACA-39and 59-GATAATGTTGCTTCAACGGAATTT-39were
used as primers for PTPN22 1858C.TS N P .T h eC RT transition at
codon 620 creates in the T1858 allele a restriction site for XcmI(New
England Biolabs, Beverly, MA. USA). The product of PCR was
digested with XcmI at 37uC for 3 hours and each digestion was
resolved on 3% agarose gel (Figure S1). Repeated typing was
performed in 10% of patient samples, with identical results in all
cases.
Meta-analysis
Identification of eligible studies and data extraction. The
electronic medical databases used for the search were Pubmed,
Embase and the Cochrane Library. In the research, we used the
Figure 1. Forest plot of the first meta-analysis. Forest plot of published studies in relation to the first meta-analysis (24 studies). The association
of the PTPN22 1858C.T SNP with RA was evaluated through the Odds ratios measures. The random effect model was used.
doi:10.1371/journal.pone.0024292.g001
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applying the following algorithm: (PTPN22 OR ‘‘protein tyrosine
phosphatase non-receptor type 22’’ OR Lyp) AND (rheumatoid
AND/OR arthritis) AND (polymorphism OR SNP). The
identification of eligible studies was carried out from 2000 until
December 2010 and it was not restricted to English language.
Studies references were also analyzed to find any study not available
from the electronic databases. A study was included in the
systematic extraction of the data if: 1. it was published before
2011; 2. it was about European patients with rheumatoid arthritis;
3. PTPN22 1858C.T SNP was evaluated and genotypes data were
clearly expressed; 4 it was a case-control study; 5. it was not a
transmission disequilibrium test in which family members were
studied. Data related to the PTPN22 1858C.T SNP in RA patients
and controls groups were extracted to perform the meta-analysis.
Data extraction and quality assessment, according to a score sheet
available for observational studies [14], were performed
independently by two different investigators.
Statistical analysis
Data regarding the PTPN22 1858C.T SNP in our RA patients
and controls groups were checked for deviation from Hardy-
Weinberg equilibrium (x
2 test). Descriptive statistics was per-
formed using frequencies and percentages. The association
between alleles and genotypes with RA was investigated applying
Exact Fisher’s Test, and calculating Odds Ratio (OR) with 95%
Confidence Interval (95%CI). Statistical analysis was performed
with SPSS 19.0 software for Windows.
Three different meta-analyses were carried out using StatDirect
statistical software Version2.7.8. The first one evaluated the
association of PTPN22 1858C.T SNP with RA considering all
published studies, present study included; the second one
presented data excluding the Italian population; the third one
considered the studies with a quality score $11, that corresponds
to the median quality score.
Forest-plots graphs were produced in order to estimate the
pooled association between the PTPN22 1858C.T SNP and RA.
The Cochran’s Q test was performed to evaluate studies
heterogeneity, thus using the random effect model when the test
highlighted differences between studies and the fixed effect model
when no significant differences were shown. Publication bias was
quantified by inspection of funnel plot and computation of Egger
and Begg test probability values [15]. Significance threshold was
set at p,0.05 (2-tailed) for all analyses.
Results
PTPN22 1858C.T SNP in Italy
The studied sample was composed of 396 RA patients and 477
controls (the power of the study was 75% for the cases). The
genotype distribution of the PTPN22 1858C.T SNP was in
Hardy-Weinberg equilibrium in both groups. Seventy-nine
percent of the RA patients were female, 67% were positive for
anti-CCP antibodies, 50% were positive for IgM RF (rheumatoid
factor), and 34% were positive for IgA RF. Moreover, 74% were
positive for at least one of the autoantibodies tested.
Figure 2. Funnel plot. Funnel plot of published studies in relation to the first meta-analysis (24 studies).
doi:10.1371/journal.pone.0024292.g002
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ancestry, showed a PTPN22 T1858 allele frequency of 5.7% in
patients compared to 3.7% in controls (OR=1.58; 95%CI=(1.01–
2.49); p=0.045) (Table 1). The frequency of positivity for anti-CCP
antibodies tended to be higher in RA patients carrying the T allele
(79.5%) compared to subjects with C/C genotype (65.6%; p=0.09).
No difference was detected in the percentage of IgA and IgM RFs
positivity between RA patients carrying the T allele and patients
with C/C genotype (data not shown).
Meta-analysis of the reported studies regarding the
PTPN22 1858C.T SNP in Europe
The association of the PTPN22 1858C.T SNP with RA in
Europe was found in 23 studies [5,7,8,16–35] (see PRISMA
Checklist S1 and Figure S2). The characteristics of each study are
shown in Table 2.
In the first meta-analysis a significant and positive association
between the PTPN22 1858C.T SNP and RA was found: pooled
OR=1.79 with 95%CI=(1.60–2.01) (Figure 1). The Cochran’s Q
test established the presence of heterogeneity (x
2=79.42, df=23,
p,0.001), therefore a random effect model was applied.
The funnel plot (Figure 2) did not show any publication bias, in
accordance with the bias tests: Begg-Mazumdar: Kendall
t=20.05, p=0.76; Egger: bias=20.55, p=0.46.
There was not a significant difference between the first meta-
analysis and the second one: combined OR=1.80 with
95%CI=(1.61–2.02) using random effect estimate (Cochran’s Q
test: x
2=79.42, df=22, p,0.001).
The studies with a quality score $11 were 14. The relationship
between PTPN22 1858C.T SNP and RA resulted even stronger:
OR=2.01, 95%CI=(1.67–2.43) using random effect model
(Cochran’s Q test: x2=61.14, df=13, p,0.001).
When looking at the T allele frequency in RA patients and
controls, we noticed a North-South gradient with higher values in
Finland, Germany, Hungary, and lower values in Spain, Italy,
Tunisia, Greece and Turkey (Figure 3 [5,7–9,16–37]).
Discussion
The association between the T1858 allele at rs2476601 in the
PTPN22 gene and RA has been documented in several cohorts,
from the USA as well from Europe [38,39], though it seems to be
less relevant in other continents [40]. When considering the
strength of the allele association in the analysis of the European
consortium, the relationship arose quite clear; however regarding
single countries, data are less clear-cut. As reported in Figure 3, a
North-South gradient seems to be present in the distribution of the
T1858 allele in both RA patients and controls, as previously
remarked by Gregersen et al. in some European populations [38].
Furthermore, it is also noteworthy that while in Germany, the
frequency of the T1858 allele was significantly higher in RA
patients (21.3%) compared to controls (10.0%; with an OR of
2.43) and the association was present irrespective of the presence
or absence of anti-CCP and RF [41], in France the European
Consortium Group provided evidence for an association of T1858
allele only with RF positive cases but not with RF negative RA
patients [36]. In Spain, there was no association with early RA but
the association was significant with the anti-CCP positive RA [6].
Genetic differences within European populations have been
once more underlined by a recent work of Rodrı ´guez-Rodrı ´guez
et al. [42]. The authors described the association of another
PTPN22 SNP, the R263Q, with RA in six different Caucasian
populations. The 1858C.T SNP was also investigated using
mostly previously published data. The T allele of the 1858C.T
SNP showed an inhomogeneous distribution among the popula-
tions taken into account, with a prevalence of 10.5% in RA
patients and 6.8% in controls in Spain, compared to 16.1% and
10.6% respectively in the other countries (Norway, UK, The
Netherlands, Germany, New Zealand).
Our data revealed a higher frequency of the T1858 allele in RA
Italian patients compared to the controls cohort. On the other
hand, the frequency in controls was lower than that observed in
France or in Germany and similar to Turkish, Greek and Tunisian
populations.
Interestingly, Mediterranean populations are genetically linked
by a common history of migrations, like the abiding one of
Saracens and Moors. In fact a recent work, estimating the
medieval North African contribution over Mediterranean coun-
tries through the analysis of the Y chromosome short tandem
repeats, suggested a general correlation between historical and
genetic data of Iberia, Sicily, Turkey and North Africa [43].
No relationship arose between the C/T-T/T genotypes
presence and auto-antibodies positivity. The demonstration of a
gain-of-function conferred by the T1858 allele in suppressing
TCR (T cell receptor) function in T cells and BCR (B cell receptor)
function in B cells raises new hypotheses on the role of tyrosine
phosphatases. The T1858 allele might increase the threshold for a
persistent activation of both autoreactive T and B cells thus
leading to a more defined autoimmune subset of RA [4]. In our
study, the trend for an association between the rs2476601 SNP
and the positivity of anti-CCP seems to move towards this
Figure 3. Geographical distribution in Europe. Geographical
distribution of the T allele frequency at PTPN22 rs2476601 SNP in
European RA patients (red) and healthy controls (black) [5,7–9,16–37].
The ‘*’ symbol refers to countries in which a statistical significant
different distribution of the PTPN22 T1858 allele among patients and
controls was noted. In Tunisia the two existing articles regarding
PTPN22 show opposite findings.
doi:10.1371/journal.pone.0024292.g003
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data at hand is the geographical issue.
In conclusion, the geographical distribution of SNPs in the
world, linked to different population origins, should be taken into
account in studies regarding genetic associations. Given that
specific therapies directed toward Lyp will be available in the near
future for various autoimmune diseases [44], there could be
clinical-therapeutic consequences as well, and, on these grounds,
the approach based on PTPN22 might be different from North to
South.
Supporting Information
Figure S1 Electrophoresis gel. Photo of the electrophoresis
gel showing intact vs. cleaved PCR-amplified fragments from
patients and controls, non-mutated, heterozygous or homozygous
for the C.T substitution. A: intact PCR-amplified fragment; B:
cleaved fragment from DNA of a patient non-mutated for the
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